Know Cancer

forgot password

A Phase II, Open-Label Study of Pazopanib (GW786034) in Patients With Relapsed or Refractory Multiple Myeloma

Phase 2
21 Years
Not Enrolling
Multiple Myeloma, Carcinoma, Renal Cell

Thank you

Trial Information

A Phase II, Open-Label Study of Pazopanib (GW786034) in Patients With Relapsed or Refractory Multiple Myeloma

Inclusion Criteria

Inclusion criteria:

- Must have diagnosis of relapsed or refractory multiple.

- bone marrow function [ANC (absolute neutrophil count) greater than 1000/mm3];
platelet count greater than or equal to 75,000/mm3.

- renal function (calculated creatinine clearance >50 mL.min, albumin less than or
equal to 500 mg).

Exclusion criteria:

- Failed more than 3 prior lines of therapy including stem cell transplant.

- Females who are pregnant or nursing.

- Unstable blood pressure.

- Significant heart conditions or history of thrombosis.

- Any unstable, pre-existing major medical condition or history of other cancers.

- Have received an investigational drug, chemotherapy, radiation treatment or surgery
within 28 days prior to entering the study.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Evaluate the safety and tolerability of GW786034 in patients with relapsed or refractory multiple myeloma (MM).

Principal Investigator

GSK Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:



Australia: National Health and Medical Research Council

Study ID:




Start Date:

January 2005

Completion Date:

December 2005

Related Keywords:

  • Multiple Myeloma
  • Carcinoma, Renal Cell
  • Pazopanib(GW786034)
  • Solid Tumors
  • Myeloma
  • Carcinoma
  • Carcinoma, Renal Cell
  • Multiple Myeloma
  • Neoplasms, Plasma Cell



GSK Investigational SiteLittle Rock, Arkansas  72205
GSK Investigational SiteSpringfield, Massachusetts  01107
GSK Investigational SiteRaleigh, North Carolina  27609
GSK Investigational SitePittsburgh, Pennsylvania  15213
GSK Investigational SiteSeattle, Washington  98133